Freeline to Present at Upcoming Investor Conferences

Rhea-AI Summary

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced its participation in two virtual investor conferences. The first, Guggenheim Healthcare Talks: 2021 Genomic Medicines and Rare Disease, is on April 1, 2021, featuring CEO Theresa Heggie discussing gene therapy challenges at 10:00 a.m. EDT. The second is the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, where Heggie will present a Company overview at 8:00 a.m. EDT. Webcasts of both events will be available on the Freeline investor relations website.

LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will attend the following virtual investor conferences:

• Guggenheim Healthcare Talks: 2021 Genomic Medicines and Rare Disease on April 1, 2021, where at 10:00 a.m. EDT, Chief Executive Officer, Theresa Heggie will participate in a panel discussion, titled ‘The low hanging fruit in gene therapy might be hard to reach – Challenges for Hemophilia A and B.’
• 20^th Annual Needham Virtual Healthcare Conference on April 13, 2021 where Theresa Heggie will present a Company overview at 8:00 a.m. EDT.

Webcasts of both the panel discussion and the Company presentation will be available on the investor relations section of the Freeline website at Freeline.life.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contact

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947

FAQ

What upcoming investor conferences will Freeline Therapeutics (FRLN) attend?

Freeline Therapeutics is attending the Guggenheim Healthcare Talks on April 1, 2021, and the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021.

Who will represent Freeline Therapeutics (FRLN) at the conferences?

CEO Theresa Heggie will participate in both conferences, discussing gene therapy challenges and presenting a company overview.

When is the Guggenheim Healthcare Talks conference for Freeline Therapeutics (FRLN)?

The Guggenheim Healthcare Talks conference is scheduled for April 1, 2021, at 10:00 a.m. EDT.

At what time will Freeline Therapeutics (FRLN) present at the Needham Virtual Healthcare Conference?

Theresa Heggie will present a company overview on April 13, 2021, at 8:00 a.m. EDT.

Where can I watch the presentations from Freeline Therapeutics (FRLN)?

Webcasts of both the Guggenheim and Needham conference presentations will be available on the Freeline investor relations section of their website.